Literature DB >> 8869051

Intramedullary subependymoma of the spinal cord.

G I Jallo1, D Zagzag, F Epstein.   

Abstract

A consecutive series of six patients underwent operative resection of intramedullary spinal cord subependymomas between January 1981 and August 1993. Three men and three women between the ages of 26 and 66 years experienced symptoms for a mean of 50 months preceding diagnosis. The locations of the tumors were predominantly cervical or cervicothoracic, except in one patient. At operation, a complete extirpation was achieved in each patient. No patient received further adjunct therapy. There has been no tumor recurrence in any patient after a mean follow-up period of 39 months. Most of the intramedullary spinal cord tumors are either ependymomas or astrocytomas. Clinical histories, physical examinations, and radiographic investigations are not conclusive for absolute diagnosis of subependymomas; however, intraoperative gross observations have shown these well-demarcated tumors to be located eccentrically within the spinal cord. Pathological examinations demonstrate tumors with sparse cellularity, clustering of cells, and dense fibrillary stroma. Proliferation studies with the mouse monoclonal antibody MIB-1 reconfirm the slow growth potential of these benign tumors.

Entities:  

Mesh:

Year:  1996        PMID: 8869051     DOI: 10.1097/00006123-199602000-00004

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  14 in total

Review 1.  Genetic basis of intramedullary spinal cord tumors and therapeutic implications.

Authors:  A T Parsa; A J Fiore; P C McCormick; J N Bruce
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

Review 2.  Subependymoma: clinical features and surgical outcomes.

Authors:  Amit Jain; Anubhav G Amin; Punya Jain; Peter Burger; George I Jallo; Michael Lim; Chetan Bettegowda
Journal:  Neurol Res       Date:  2012-06-28       Impact factor: 2.448

Review 3.  Spinal cord ependymoma: a review of the literature and case series of ten patients.

Authors:  Emma Celano; Arsalaan Salehani; James G Malcolm; Erik Reinertsen; Constantinos G Hadjipanayis
Journal:  J Neurooncol       Date:  2016-05-06       Impact factor: 4.130

Review 4.  Recent Advances in the Classification and Treatment of Ependymomas.

Authors:  Heather Leeper; Michelle M Felicella; Tobias Walbert
Journal:  Curr Treat Options Oncol       Date:  2017-08-10

Review 5.  Hemangioblastomas and other uncommon intramedullary tumors.

Authors:  D J Miller; I E McCutcheon
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

6.  A case of recurrent subependymoma with subependymal seeding: case report.

Authors:  Ho Jun Seol; Sung-Kyun Hwang; Yoon La Choi; Je G Chi; Hee-Won Jung
Journal:  J Neurooncol       Date:  2003-05       Impact factor: 4.130

7.  Unusual appearance and presentation of supratentorial subependymoma in an adult patient.

Authors:  Ahmed K Abdel-Aal; Maysoon F Hamed; Nasser S Al Naief; Surjith Vattoth; Asim Bag
Journal:  J Radiol Case Rep       Date:  2012-08-01

Review 8.  Thoracolumbar intramedullary subependymoma with multiple cystic formation: a case report and review.

Authors:  Motoyuki Iwasaki; Kazutoshi Hida; Takeshi Aoyama; Kiyohiro Houkin
Journal:  Eur Spine J       Date:  2012-05-05       Impact factor: 3.134

9.  Bamboo Leaf Sign as a Sensitive Magnetic Resonance Imaging Finding in Spinal Subependymoma: Case Report and Literature Review.

Authors:  Hiroyuki Toi; Yukari Ogawa; Keita Kinoshita; Satoshi Hirai; Hiroki Takai; Keijiro Hara; Nobuhisa Matsushita; Shunji Matsubara; Masaaki Uno
Journal:  Case Rep Neurol Med       Date:  2016-12-15

10.  Genome-wide analysis of subependymomas shows underlying chromosomal copy number changes involving chromosomes 6, 7, 8 and 14 in a proportion of cases.

Authors:  Kathreena M Kurian; David T W Jones; Faye Marsden; Sam W S Openshaw; Danita M Pearson; Koichi Ichimura; V Peter Collins
Journal:  Brain Pathol       Date:  2008-04-07       Impact factor: 6.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.